IFRX

InflaRx NV

1.86

Jul 17 • 03:59PM ET -0.05 (-2.88%)

1.86

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Biotechnology Germany Micro NASD

Peers: KPTI ADAG CAMP CNTN CNTX PLYX PRQR RNA TENX TLSA

| Held by: QQQS

Scroll to Statements

Index	-
Market Cap	273.23M
Enterprise Value	228.32M
Income	-
Sales	-
Book/sh	0.59
Cash/sh	0.31
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	65
IPO	Nov 08, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.16
P/C	5.96
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.16
Current Ratio	4.16
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-0.47
EPS next Q	-0.07
EPS this Y	55.42%
EPS next Y	-35.41%
EPS next 5Y	14.27%
EPS past 3/5Y	-2.98% 11.77%
Sales past 3/5Y	- -
EPS Y/Y TTM	-40.62%
Sales Y/Y TTM	-
EPS Q/Q	72.20%
Sales Q/Q	-100.00%
Earnings	May 07 BMO
EPS/Sales Surpr.	32.03% -100.00%

Insider Own	12.79%
Insider Trans	0.00%
Inst Own	18.04%
Inst Trans	0.50%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.06%
SMA50	-13.28%
SMA200	32.56%
Trades

Shs Outstand	147.29M
Shs Float	128.45M
Short Float	6.32%
Short Ratio	3.94
Short Interest	8.11M
52W High	2.95 -37.10%
52W Low	0.74 150.47%
Volatility	6.41% 10.39%
ATR (14)	0.19
RSI (14)	41.32
Beta	2.48
Rel Volume	0.36
Avg Volume	2.06M
Volume	749,225

Perf Week	-9.51%
Perf Month	15.94%
Perf Quarter	54.58%
Perf Half Y	73.36%
Perf YTD	83.66%
Perf Year	113.73%
Perf 3Y	-54.20%
Perf 5Y	-28.93%
Perf 10Y	-
Recom	1.50
Target Price	7.81
Prev Close	1.91
Price	1.86
Change	-2.88%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-26	Upgrade	Raymond James	Outperform → Strong Buy	$9
Apr-24-26	Resumed	Oppenheimer	Outperform	$7 → $5
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2
Sep-02-25	Resumed	H.C. Wainwright	Buy	$6
May-29-25	Downgrade	Raymond James	Strong Buy → Outperform	$2
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-23	Upgrade	Guggenheim	Neutral → Buy	$8
Feb-28-22	Downgrade	Guggenheim	Buy → Neutral
Oct-28-21	Upgrade	Raymond James	Outperform → Strong Buy	$10 → $14
Mar-11-21	Upgrade	Guggenheim	Neutral → Buy	$16
Nov-06-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$7 → $10
Oct-08-20	Initiated	H.C. Wainwright	Buy	$11
Jun-17-20	Initiated	BTIG Research	Buy	$12
Apr-30-20	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-05-19	Downgrade	SunTrust	Buy → Hold	$55 → $5
Jun-05-19	Downgrade	Robert W. Baird	Outperform → Neutral	$58 → $6
Jun-05-19	Downgrade	JP Morgan	Overweight → Underweight	$67 → $9
Jun-05-19	Downgrade	Guggenheim	Buy → Neutral	$65 → $6
Jun-05-19	Downgrade	BMO Capital Markets	Outperform → Market Perform	$5
Jan-29-19	Initiated	Robert W. Baird	Outperform

Show Previous Ratings

Jun-30-26 07:30AM	InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos (GlobeNewswire)
May-08-26 08:15AM	InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares (GlobeNewswire)
May-06-26 08:30AM	InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares (GlobeNewswire) +26.90%
08:25AM	InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases (GlobeNewswire)
May-04-26 07:30AM	InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes (GlobeNewswire)
07:30AM	Loading…
May-01-26 07:30AM	InflaRx to Report First Quarter 2026 Results on May 7, 2026 (GlobeNewswire)
Apr-28-26 07:30AM	InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Apr-09-26 07:30AM	InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor (GlobeNewswire) +8.42%
Apr-07-26 03:35PM	Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization (Exec Edge)
Mar-31-26 07:30AM	InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium (GlobeNewswire) +7.54%
Mar-30-26 07:30AM	InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire) -8.79%
Mar-19-26 07:30AM	InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones (GlobeNewswire)
Mar-18-26 07:30AM	InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-13-26 05:00PM	InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Mar-12-26 07:30AM	InflaRx to Report Full Year 2025 Results on March 19, 2026 (GlobeNewswire)
07:30AM	Loading…
Feb-26-26 07:30AM	InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
06:54AM	InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference (MarketBeat)
Feb-13-26 10:02PM	InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit (MarketBeat)
Jan-29-26 07:30AM	InflaRx Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-08-26 12:22PM	InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway (Benzinga) -9.17%
08:00AM	InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation (GlobeNewswire)
Dec-30-25 07:30AM	InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum (GlobeNewswire)
Dec-11-25 07:30AM	InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 (GlobeNewswire)
Nov-10-25 07:30AM	InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) (GlobeNewswire) +28.46%
Nov-07-25 04:05PM	InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-05-25 05:35PM	Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-04-25 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.97%
Oct-21-25 07:20AM	InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Sep-12-25 08:30AM	InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -14.29%
Aug-21-25 07:30AM	InflaRx Announces Participation in September Investor Conferences (GlobeNewswire)
08:45AM	Loading…
Aug-07-25 08:45AM	InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-25 08:10AM	Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 07:30AM	InflaRx to Report Second Quarter 2025 Results on August 7, 2025 (GlobeNewswire)
Jul-25-25 12:22PM	InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected (Insider Monkey) +5.72%
Jul-11-25 04:15PM	InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-28-25 01:30AM	InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum (GlobeNewswire) -59.86%
May-22-25 07:30AM	InflaRx to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.69%
May-07-25 07:30AM	InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.45%
May-06-25 09:35AM	Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-30-25 07:30AM	InflaRx to Report First Quarter 2025 Results on May 7, 2025 (GlobeNewswire) +17.24%
Apr-02-25 03:33PM	Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds? (Insider Monkey) +9.52%
Mar-26-25 09:35AM	InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.77%
Mar-20-25 07:30AM	InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones (GlobeNewswire)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha) +5.79%
Mar-07-25 08:00AM	InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting (GlobeNewswire)
Feb-28-25 09:00AM	InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting (GlobeNewswire)
Feb-25-25 07:30AM	InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-18-25 04:01PM	InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) -5.75%
Feb-13-25 09:45PM	InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) +5.06% -25.93%
04:01PM	InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
Jan-23-25 07:30AM	InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -5.20%
Jan-16-25 11:05AM	InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS (Pharmaceutical Technology)
Jan-15-25 12:30PM	InflaRx Receives European Commission Approval for GOHIBIC (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) (GlobeNewswire) +7.69%
Jan-07-25 07:30AM	InflaRx Announces Participation in January Events in San Francisco (GlobeNewswire) +11.35%
Dec-20-24 07:30AM	InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 (GlobeNewswire) +5.16%
Nov-19-24 06:29PM	Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? (Insider Monkey) +10.34% +6.25%
Nov-15-24 07:51AM	InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (GlobeNewswire)
Nov-12-24 11:00PM	InflaRx Reports Q3 2024 Financial Results and Progress (TipRanks) +13.25%
Nov-09-24 07:41AM	InflaRx expects cash to fund operations into 2026 (TipRanks)
Nov-08-24 08:40AM	InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 07:30AM	InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-25-24 07:30AM	InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-03-24 07:30AM	InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases (GlobeNewswire)
Aug-27-24 07:30AM	InflaRx Announces Participation in September Investor Events (GlobeNewswire)
Aug-08-24 08:50AM	InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 07:30AM	InflaRx to Report Second Quarter 2024 Results on August 8, 2024 (GlobeNewswire)
Jul-30-24 07:30AM	InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases (GlobeNewswire)
Jun-24-24 08:02AM	InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) (GlobeNewswire) +8.44%
Jun-05-24 12:00PM	InflaRx Hosts R&D Event Highlighting the Promise of INF904 (GlobeNewswire)
May-21-24 02:30PM	InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators (GlobeNewswire)
May-08-24 11:57AM	IFRX Stock Earnings: InflaRx Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:30AM	InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-24 07:30AM	InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 (GlobeNewswire)
Apr-24-24 07:30AM	InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event (GlobeNewswire)
Mar-21-24 11:53AM	IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.88%
08:45AM	InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans (GlobeNewswire)
Mar-19-24 07:30AM	InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 (GlobeNewswire) +12.67%
Feb-22-24 07:30AM	InflaRx Appoints Jan Medina as Head of Investor Relations (GlobeNewswire)
Jan-25-24 07:30AM	InflaRx Announces Initiation of its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients (GlobeNewswire) -6.25%
Jan-04-24 07:00AM	InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 (GlobeNewswire) +14.38%
Dec-01-23 09:55AM	Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing (Zacks)
Nov-28-23 09:35AM	After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX) (Zacks)
Nov-06-23 09:35AM	InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:30AM	InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum (GlobeNewswire)
Nov-01-23 07:30AM	InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-23 07:12PM	12 Best German Stocks To Buy Now (Insider Monkey)
Sep-11-23 07:00AM	InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 (GlobeNewswire)
Sep-01-23 02:38PM	InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why (Zacks) +5.06%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 07:30AM	InflaRxs Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA) (GlobeNewswire) +9.89%
Aug-10-23 07:30AM	InflaRx Reports Second Quarter 2023 Financial Results & Operating Update (GlobeNewswire) +9.59%
Jun-28-23 07:30AM	InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer (GlobeNewswire)
Jun-21-23 07:00AM	InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients (GlobeNewswire)
May-11-23 07:30AM	InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update (GlobeNewswire) +7.46%
May-03-23 07:14AM	InflaRx N.V.'s (NASDAQ:IFRX) Profit Outlook (Simply Wall St.)

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Ph.D.Prof. Niels C. Riedemann M.D.

Co-FounderProf. Renfeng Guo M.D.

Chief Financial OfficerDr. Thomas Taapken Ph.D.

Senior VP and Global Head of Regulatory Affairs & ComplianceMs. Derval O'Carroll

Head of Investor Relations & VPMr. Jan Medina CFA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IFRX

InflaRx NV

Upgrade your Finviz experience